RAPPORT THERAPEUTICS INC (RAPP) Stock Overview
USA - NASDAQ:RAPP - US75383L1026 - Common Stock
RAPP Key Statistics, Chart & Performance
The current stock price of RAPP is 26.74 USD. In the past month the price increased by 15.26%. In the past year, price increased by 21.27%.
RAPP Latest News, Press Relases and Analysis
RAPP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 52.96 | 809.55B | ||
| JNJ | JOHNSON & JOHNSON | 19.11 | 460.19B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 19.15 | 263.67B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 15.08 | 260.74B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.81 | 253.71B | ||
| MRK | MERCK & CO. INC. | 11.36 | 218.56B | ||
| PFE | PFIZER INC | 7.45 | 143.50B | ||
| SNY | SANOFI-ADR | 11.05 | 118.98B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.64 | 90.94B | ||
| GSK | GSK PLC-SPON ADR | 9.65 | 87.43B | ||
| ZTS | ZOETIS INC | 23.05 | 63.55B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.29 | 44.47B |
Related stock screener links
About RAPP
Company Profile
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. The company is headquartered in Boston, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2024-06-07. The company has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The company is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Company Info
RAPPORT THERAPEUTICS INC
99 High Street, Suite 2100
Boston MASSACHUSETTS US
Employees: 69
Phone: 18573218020
RAPPORT THERAPEUTICS INC / RAPP FAQ
What is the stock price of RAPPORT THERAPEUTICS INC today?
The current stock price of RAPP is 26.74 USD. The price decreased by -1.18% in the last trading session.
What is the ticker symbol for RAPPORT THERAPEUTICS INC stock?
The exchange symbol of RAPPORT THERAPEUTICS INC is RAPP and it is listed on the Nasdaq exchange.
On which exchange is RAPP stock listed?
RAPP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RAPPORT THERAPEUTICS INC stock?
14 analysts have analysed RAPP and the average price target is 52.75 USD. This implies a price increase of 97.26% is expected in the next year compared to the current price of 26.74. Check the RAPPORT THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RAPPORT THERAPEUTICS INC worth?
RAPPORT THERAPEUTICS INC (RAPP) has a market capitalization of 1.23B USD. This makes RAPP a Small Cap stock.
How many employees does RAPPORT THERAPEUTICS INC have?
RAPPORT THERAPEUTICS INC (RAPP) currently has 69 employees.
What are the support and resistance levels for RAPPORT THERAPEUTICS INC (RAPP) stock?
RAPPORT THERAPEUTICS INC (RAPP) has a support level at 26.73 and a resistance level at 29.14. Check the full technical report for a detailed analysis of RAPP support and resistance levels.
Should I buy RAPPORT THERAPEUTICS INC (RAPP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RAPP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RAPP, evaluating the profitability, health, valuation and growth aspects
- RAPPORT THERAPEUTICS INC (RAPP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RAPPORT THERAPEUTICS INC (RAPP) Sales and EPS estimates to see what analysts future expectations are.
- RAPPORT THERAPEUTICS INC (RAPP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RAPPORT THERAPEUTICS INC (RAPP) Insider and Institutional Ownership to learn about the owners and their transactions.
- RAPPORT THERAPEUTICS INC (RAPP) Stock Chart to make your own analysis
- RAPPORT THERAPEUTICS INC (RAPP) Latest news and press-releases to stay up to date.
Does RAPPORT THERAPEUTICS INC (RAPP) stock pay dividends?
RAPP does not pay a dividend.
When does RAPPORT THERAPEUTICS INC (RAPP) report earnings?
RAPPORT THERAPEUTICS INC (RAPP) will report earnings on 2025-11-05.
What is the Price/Earnings (PE) ratio of RAPPORT THERAPEUTICS INC (RAPP)?
RAPPORT THERAPEUTICS INC (RAPP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.5).
What is the Short Interest ratio of RAPPORT THERAPEUTICS INC (RAPP) stock?
The outstanding short interest for RAPPORT THERAPEUTICS INC (RAPP) is 7.21% of its float. Check the ownership tab for more information on the RAPP short interest.
RAPP Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to RAPP. When comparing the yearly performance of all stocks, RAPP is one of the better performing stocks in the market, outperforming 91.33% of all stocks.
RAPP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RAPP. RAPP has a great financial health rating, but its profitability evaluates not so good.
RAPP Financial Highlights
Over the last trailing twelve months RAPP reported a non-GAAP Earnings per Share(EPS) of -2.5. The EPS decreased by -284.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.93% | ||
| ROE | -33.51% | ||
| Debt/Equity | 0 |
RAPP Forecast & Estimates
14 analysts have analysed RAPP and the average price target is 52.75 USD. This implies a price increase of 97.26% is expected in the next year compared to the current price of 26.74.